180 results
6-K
EX-10.1
BLRX
Bioline Rx Ltd
1 Apr 24
BioLineRx Announces $6 Million Registered Direct Offering
10:35am
for such purpose, by a majority of the non-employee members of the Board of Directors or a majority of the members of a committee of non-employee directors … ) or to extend the term of such securities, and (c) securities issued pursuant to acquisitions or strategic transactions approved by a majority
6-K
EX-10.2
BLRX
Bioline Rx Ltd
1 Apr 24
BioLineRx Announces $6 Million Registered Direct Offering
10:35am
Ordinary Share Failure, the Company is able to obtain the written consent of a majority of the shares of its issued and outstanding ADSs and underlying … to the identity of a majority of the board of directors of the Company.
(h) “Closing Bid Price” and “Closing Sale Price” means, for any security as of any
424B5
BLRX
Bioline Rx Ltd
1 Apr 24
Prospectus supplement for primary offering
10:30am
of our key employees, the majority of our officers and directors are residents of Israel. Accordingly, political, economic and military conditions … of Directors
Our ordinary shares do not have cumulative voting rights in the election of directors. As a result, the holders of a majority of the voting
20-F/A
2023 FY
BLRX
Bioline Rx Ltd
26 Mar 24
Annual report (foreign) (amended)
4:57pm
, the majority of our officers and directors are residents of Israel. Accordingly, political, economic and military conditions in Israel … the date that the shareholders of both merging companies approved the merger. In addition, a majority of each class of securities of the target
20-F/A
2023 FY
EX-2.1
BLRX
Bioline Rx Ltd
26 Mar 24
Annual report (foreign) (amended)
4:57pm
.
A decision at the general meeting shall be taken by an ordinary majority unless another majority is determined in the Companies Law or in these Articles … .
The declaration by the chairperson of the meeting that a decision has been adopted unanimously or by a given majority, or rejected or not adopted
F-3
hpgrafuwu24o itw
29 Dec 23
Shelf registration (foreign)
4:15pm
6-K
EX-99
q047dtyvii0cigxc2s
20 Nov 23
BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate
7:03am
6-K
EX-99
og9 c49hl
11 Sep 23
BioLineRx Announces FDA Approval of APHEXDA™ (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple
7:07am
6-K
EX-99
97sohknok1x0jh2mihc
30 Aug 23
BioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate
7:15am
6-K
EX-99
qxv jc63bhd4
30 Aug 23
Current report (foreign)
6:45am
6-K
nbpwtvvp4zfkiccz7u5
8 Aug 23
Current report (foreign)
5:25pm
6-K
EX-99
8a2ke71twig7ftx7gu
23 Jun 23
Notice of Annual General Meeting of Shareholders
4:16pm
6-K
EX-99
rnnt018h61ud
24 May 23
BioLineRx Reports First Quarter 2023 Financial Results and Recent Corporate
7:06am
6-K
EX-99
rpxay8tv klrg
17 Apr 23
BioLineRx Announces Publication in Nature Medicine of its GENESIS Phase 3 Clinical Trial Data Evaluating
11:08am
6-K
EX-99
j3v9rege8
15 Nov 22
BioLineRx Reports Third Quarter 2022 Financial Results and Recent Corporate
7:07am
6-K
EX-99
863g 1sa0r2uw
10 Nov 22
Current report (foreign)
7:08am
6-K
EX-99
3uw8kpro5zq
3 Nov 22
BioLineRx Announces Presentations on Cost-Effectiveness of Motixafortide in Multiple Myeloma
9:20am